Physician profile
Jonathan E Aviv
NPI 1427194000
$4,530.91
in general payments reported to CMS, 2019-2025
27 companies · $933 in 2025
The $933 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $399 · 2021: $332 · 2022: $706 · 2023: $871 · 2024: $894 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,035.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $559.25 | 2020-2025 | Tezspire, Fasenra |
| Optinose US, INC. | $557.14 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $366.71 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $348.99 | 2024 | Voquezna |
| Hikma Pharmaceuticals USA | $182.27 | 2023-2024 | Ryaltris |
| Glaxosmithkline, LLC. | $179.61 | 2020-2023 | Nucala, Trelegy Ellipta |
| Aerin Medical INC. | $168.37 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $158.15 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $150.00 | 2025 | Neffy |
| Kaleo, INC. | $118.57 | 2019-2024 | Auvi-Q |
| Stryker Corporation | $115.15 | 2019-2025 | Xpress Loprofile |
| Alk-Abello, INC | $100.67 | 2019-2021 | |
| Harmony Biosciences LLC | $98.31 | 2022-2025 | Wakix |
| Itamar Medical INC | $49.80 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.31 | 2021-2022 | |
| 3b Medical, INC. | $44.18 | 2023-2024 | Luna |
| Smith+Nephew, INC. | $41.44 | 2025 | Tula |
| Resmed Corp | $28.47 | 2023 | |
| Integra Lifesciences Corporation | $27.72 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Aimmune Therapeutics, INC. | $26.92 | 2022 | |
| Incyte Corporation | $24.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.23 | 2019 | |
| Circassia INC. | $19.73 | 2020 | |
| Galderma Laboratories, L.P. | $19.57 | 2025 | Nemluvio |
| Acclarent, INC | $18.71 | 2019 | |
| Lilly USA, LLC | $17.66 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Aviv listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.